Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL)

 

 Buy Article Permissions and Reprints

Abstract

Paragangliomas (PGLs) are neuroendocrine tum­ors that arise embryologically from the neural crest. Sympathetic PGLs can be located in the thoracic-abdominal region while parasympathetic PGLs are mainly situated in the head and neck region. Most PGLs are sporadic, but in 30% of cases they are hereditary (associated with mutations of SDHB, SDHC, SDHD, SDHAF2, SDHA, TMEM, MAX, and VHL); they can be classified into 4 different paraganglioma syndromes: PGL1, PGL2, PGL3, and PGL4. Surgery is the treatment of choice for both sympathetic and parasympathetic PGLs. Other types of treatment include medical agents (such as gemcitabine, cisplatin, or sunitinib) and radiotherapy (external-beam radiotherapy or stereotactic surgery). Surgery and radiotherapy, however, can cause important side effects such as vascular complications and peripheral nerve damage (hypoglossal, recurrent laryngeal, glossopharyngeal, and vagus). Another possible treatment option is the use of peptide receptor radionuclide therapy (PRRT), including PRRT with ¹⁷⁷Lu-DOTATATE. We studied 4 patients with hereditary nonmetastatic paraganglioma syndrome type 1 (PGL1), with progressive disease, in whom surgical excision was not possible. They were treated with ¹⁷⁷Lu-DOTATATE (3–5 cycles) and all had a partial response (PR) or a stable disease (SD) to the treatment. In conclusion, a good alternative treatment when surgical or radiation therapy are contraindicated could be radiometabolic therapy with ¹⁷⁷Lu-DOTATATE.

• References

• 1 Cascón A, López-Jiménez E, Landa I, Leskelä S, Leandro-García LJ, Maliszewska A, Letón R, de la Vega L, García-Barcina MJ, Sanabria C, Alvarez-Escolá C, Rodríguez-Antona C, Robledo M. Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma. Horm Metab Res 2009; 41: 672-675
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Qin Y, Buddavarapu K, Dahia PL. Pheochromocytomas: from genetic diversity to new paradigms. Horm Metab Res 2009; 41: 664-671
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Opocher G, Schiavi F. Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metabol 2010; 24: 943-956
  CrossrefPubMedGoogle Scholar
• 4 Neumann HP, Sullivan M, Winter A, Malinoc A, Hoffmann MM, Boedeker CC, Bertz H, Walz MK, Moeller LC, Schmid KW, Eng C. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab 2011; 96: E1279-E1282
  CrossrefPubMedGoogle Scholar
• 5 Comino-Méndez I, Gracia-Aznàrez FJ, Schiavi F, Landa I, Leandro-Garcìa LJ, Letòn R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gòmez-Grana A, de Cubas AA, Inglada-Pérez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernàndez-Lavado R, Dìaz JA, Gòmez-Morales M, Gonzàlez-Neira A, Roncador G, Rodrìguez-Antona C, Benìtez J, Mannelli M, Opocher G, Robledo M, Cascòn A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011; 43: 663-667
  CrossrefPubMedGoogle Scholar
• 6 Zeitler DM, Glick J, Har-El G. Preoperative embolization in carotid body tumour surgery: is it required?. Ann Otol Rhinol Laryngol 2010; 119: 279-283
  PubMedGoogle Scholar
• 7 Garibaldi E, Bresciani S, Panaia R, Demastro E, Malinverni G, Gabriele P. Hereditary paraganglioma syndrome associated with SDHD gene mutations: a patient with multicentric presentation treated with radiotherapy. Case report. Tumori 2011; 97: 214-220
  PubMedGoogle Scholar
• 8 Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ. Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheocromocytoma. J Clin Endocrinol Metab 2009; 94: 5-9
  CrossrefPubMedGoogle Scholar
• 9 Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, Baio SM, Sansovini M, Paganelli G. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-1856
  CrossrefPubMedGoogle Scholar
• 10 Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O’dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46: 62-66
  PubMedGoogle Scholar
• 11 Julka PK, Doval DC, Gupta S, Rath GK. Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines. Br J Radiol 2008; 81: 444-449
  CrossrefPubMedGoogle Scholar
• 12 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplar R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
  CrossrefPubMedGoogle Scholar
• 13 Bravo EL, Kalmadi SR, Gill I. Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Horm Metab Res 2009; 41: 703-706
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Santarpia L, Habra MA, Jiménez C. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm Metab Res 2009; 41: 680-686
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Chrisoulisou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine Relat Cancer 2007; 14: 569-585
  CrossrefPubMedGoogle Scholar
• 16 Havekes B, Lai EW, Corssmit EPM, Romijn JA, HJLM Timmers, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Im 2008; 52: 419-429
  PubMedGoogle Scholar
• 17 Rufini V, Castaldi P, Treglia G, Perotti G, Gross MD, Al-Nahhas A, Rubello D. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed & Pharmacol 2008; 62: 139-146
  PubMedGoogle Scholar
• 18 Duet M. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 2003; 44: 1767-1774
  PubMedGoogle Scholar
• 19 Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Im 2008; 52: 334-340
  PubMedGoogle Scholar
• 20 Van Essen M, Krenning E, Kooij P, Bakker WH, Feelders RA, de Herder WW, Wolbers JG, Kwekkeboom DJ. Effects of Therapy with [177Lu-DOTA0, TYR 3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma. J Nucl Med 2006; 47: 1599-1606
  PubMedGoogle Scholar
• 21 Cecchin D, Schiavi F, Fanti S, Favero M, Manara R, Fassina A, Briani C, Allegri V, Sansovini M, Bui F, Paganelli G, Opocher G. Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas. J Clin Oncol 2011; 29: 171-174
  CrossrefPubMedGoogle Scholar